TAK, US8740602052

Takeda stock: Analysts lift target for Takeda stock to USD 20.74

Published on 10/21/2026 at 17:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Takeda schedules fiscal 2026 second-quarter results for October 29. Takeda stock costs EUR 17.80 on October 21, 2026 at 5:11 p.m. CEST.

Analysts and earnings date

TradingView reported an average target increase from USD 20.58 to USD 20.74 on October 15, 2026.
Takeda will present fiscal 2026 second-quarter results on October 29, 2026.
Takeda stock was trading at EUR 17.80 at Lang & Schwarz on October 21, 2026 at 5:11 p.m. CEST, 0.89 percent below its USD 20.13 52-week high on the NYSE.
MarketBeat reported July 30 quarterly earnings of USD 0.95 per share against USD 0.41 expected.

TAK, US8740602052, Illustration mit AI erstellt.

Takeda Pharmaceutical Company Limited (ISIN US8740602052) is heading toward its fiscal 2026 second-quarter results after the average analyst target rose from USD 20.58 to USD 20.74. TradingView reported the change on October 15, 2026, based on estimates from 14 analysts. The stock was trading at EUR 17.80 at Lang & Schwarz on October 21, 2026 at 5:11 p.m. CEST.

Target rises before results

The USD 20.74 average target stands 3.96 percent above the NYSE quote of USD 19.95 at 11:22 a.m. ET on October 21, 2026. TradingView said forecasts ranged from USD 16.96 to USD 23.36 per share, while 10 analysts rated the stock Buy and seven rated it Hold.

Stock near its yearly high

Takeda's NYSE stock had traded at USD 20.13 for a new 52-week high on October 21, 2026, according to MarketBeat. The USD 19.95 quote was 0.89 percent below that level. The same report listed a market capitalization of USD 63.5 billion and a price-to-earnings ratio of 11.67.

October 29 sets the next test

Takeda announced on October 15, 2026 that it will present its fiscal 2026 second-quarter results on October 29, 2026. The company said the presentation and question-and-answer session will begin at 7:00 p.m. JST, with materials scheduled for release at 3:30 p.m. JST. The date matters because the latest quarterly comparison remains the July 30 report, when MarketBeat recorded earnings of USD 0.95 per share against a USD 0.41 consensus estimate and revenue of USD 7.50 billion against USD 7.13 billion expected.

Comparison with peers

Takeda Pharmaceutical: minus 0.62 percent, P/E 56.29, market capitalization USD 63.5 billion. Johnson & Johnson (NYSE, USD): minus 1.51 percent, P/E 38.71, market capitalization USD 615.6 billion. Pfizer (NYSE, USD): minus 1.01 percent, P/E 39.35, market capitalization USD 169.9 billion.

Trading level and next date

The combination of a USD 20.74 target and the October 29 reporting date gives investors two separate reference points. The target sits above the current NYSE quote, while the euro quotation remained below its USD 20.13 yearly high after the latest US session indication.

Takeda was trading at EUR 17.80 at Lang & Schwarz on October 21, 2026 at 5:11 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Takeda stock.